文献速递急性肾损伤慢性肾脏病遗传性与小管间质肾病

肾脏芯片与类器官模型:利用机械力推动转化肾脏生物学

Kidney-On-Chip and Organoid Models: Harnessing Mechanical Forces for Translational Kidney Biology.
PubMed 文献 · J Am Soc Nephrol · 2026-09-08

美国FDA现代化法案及2025年联邦政策变化推动非动物、人源化模型用于临床前药物开发和毒性筛查。该综述讨论肾脏芯片和诱导多能干细胞来源肾脏类器官作为生理相关平台,用于模拟肾毒性、肾脏发育和病理生理,并探讨生物工程方法解决类器官成熟度、可扩展性和血管化等局限。

要点

  • 肾脏芯片可重现流体剪切应力和机械应变等体内机械力,实现实时功能读数。
  • iPSC来源肾脏类器官重现肾单位三维结构和输尿管芽分支,培养数月保持结构稳定。
  • 整合临床数据库和机器学习与芯片验证可提高转化相关性。

核心结论

  • 工程师、生物学家和医师科学家的跨学科合作对将生物工程肾脏模型转化为临床和治疗应用至关重要。

研究设计与样本

  • 综述讨论了肾脏芯片和诱导多能干细胞来源肾脏类器官作为生理相关平台,用于模拟肾毒性、肾脏发育和病理生理。

主要发现

  • 肾脏芯片模型重现细胞经历的流体剪切应力和机械应变等体内机械力,实现肾小球滤过、肾小管重吸收和肾毒性反应的实时功能读数。
  • 诱导多能干细胞来源肾脏类器官重现肾单位节段的三维结构和输尿管芽分支模式,展示选择性转运、毒性反应和培养数月内的结构稳定性。
  • 生物工程方法包括类器官芯片模型、生物打印和多器官芯片集成,可解决类器官成熟度、可扩展性和血管化等局限。
  • 整合公开临床数据库和机器学习方法与芯片验证可提高转化相关性。

临床怎么用

  • 肾脏芯片和类器官模型可作为临床前药物开发和毒性筛查的人源化平台,模拟肾毒性和肾脏生理功能。

局限性

  • 动物模型无法在发病机制中解耦生物力学和生化效应;体外系统缺乏生理相关微环境。
  • 类器官存在成熟度、可扩展性和血管化等局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The US Food and Drug Administration Modernization Act and the federal policy changes in 2025 have signaled a shift toward the use of nonanimal, human-centered models for preclinical drug development and toxicity screening, emphasizing 3D cell-based, organ-on-chip, and organoid platforms as alternatives to animal models. While animal models have advanced our understanding of disease mechanisms, they do not allow decoupling of biomechanical and biochemical effects during pathogenesis. In vitro systems offer improved accessibility but lack physiologically relevant microenvironments. In this review, we discuss how kidney-on-chip and induced pluripotent stem cell-derived kidney organoid models serve as physiologically relevant platforms for modeling nephrotoxicity, kidney development, and pathophysiology. Kidney-on-chip models recapitulate in vivo mechanical forces, such as fluid shear stress and mechanical strain, experienced by cells, enabling real-time functional readouts of glomerular filtration, tubular reabsorption, and nephrotoxic response. Integrating on-chip platforms with patient-derived induced pluripotent stem cells and differentiated kidney cell types allows human-relevant responses unavailable in static culture. Induced pluripotent stem cell-derived kidney organoids recapitulate the 3D architecture of nephron segments and ureteric bud branching patterns, demonstrating selective transport, toxicity responses, and structural stability over months in culture. We detail how bioengineering approaches, including organoid-on-chip models, bioprinting, and multi-organ-on-chip integration, could address the limitations of organoids, such as maturity, scalability, and vascularization. We discuss how integrating publicly available clinical databases and machine learning approaches with on-chip validation can improve translational relevance. We conclude that interdisciplinary collaboration between engineers, biologists, and physician scientists remains essential to translating bioengineered kidney models into clinical and therapeutic applications.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Daily A, Anandakrishnan N, Haydak J, et al. Kidney-On-Chip and Organoid Models: Harnessing Mechanical Forces for Translational Kidney Biology. J Am Soc Nephrol. 2026. PMID: 42709582. doi:10.1681/ASN.0000001272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。